2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Breeze Acquisition Corp. II's Audit Committee concluded on August 28, 2026 that the audited balance sheet as of May 14, 2026, included in a June 2, 2026 Form 8-K, should no longer be relied upon due to an accounting error tied to legal advisor fees. The company also reported a material weakness in internal controls over contract review and said it disbursed cash under an obligation that did not exist.
The Audit Committee made the conclusion on August 28, 2026, after discussion with the company's auditor, CBIZ CPAs P.C.
The restatement removes $1,957,000 of accrued expenses and $93,000 of additional paid-in capital, and reclassifies the $1,150,000 cash payment as a receivable due from the Sponsor.
The company identified a material weakness in internal control over financial reporting and is implementing remediation procedures.
Restated financial statements are to be filed in an amendment to this Form 8-K and in the Form 10-Q for the quarter ended June 30, 2026.
Deckers Outdoor entered into a First Amendment to its credit agreement with Citibank, N.A. as administrative agent, effective August 27, 2026. The amendment increases unsecured revolving commitments to $500 million, extends the maturity to August 27, 2031, and lowers the commitment fee on unused amounts. The filing says proceeds will be used for working capital and general corporate purposes.
Unsecured revolving commitments increased to $500 million
Maturity extended to August 27, 2031, subject to lender extension conditions
Commitment fee on unused amounts now 0.10% to 0.175% per annum, based on total net leverage ratio
Benelux subsidiary Deckers Benelux B.V. released as a borrower
Sweetgreen's board and Compensation Committee approved a Severance Plan effective August 27, 2026, and all executive officers signed participation agreements that day. The plan sets lump-sum severance and benefits for designated employees if they are terminated without cause or resign for good reason, with larger payouts if this happens within 12 months after a change in control.
Effective date of the Severance Plan is August 27, 2026.
CFO Jamie McConnell and COO Jason Cochran are Tier II Participants: 1 and 0.5 times annual base salary in the same circumstances.
The plan supersedes existing severance provisions in employment agreements unless a participation agreement states otherwise.
Forum Energy Technologies filed a legal opinion from Gibson, Dunn & Crutcher LLP, issued for a prospectus supplement it filed with the SEC on August 28, 2026 under its Form S-3 registration statement. The filing is administrative and does not state the size, price, or purpose of any offering, so it gives shareholders no new financial results.
Exhibit 5.1 is a Gibson, Dunn & Crutcher LLP opinion tied to a prospectus supplement filed August 28, 2026
The opinion relates to Form S-3 registration statement File No. 333-298624
Exhibit 23.1 is the law firm's consent, included within Exhibit 5.1
Spero Therapeutics entered an at-the-market share sale agreement with Jefferies LLC as agent on August 28, 2026, allowing it to sell common stock up to $100 million once its $300 million universal shelf registration statement is declared effective. The company also terminated its prior Cantor Fitzgerald at-the-market agreement effective the same day, with no termination penalties and no shares sold under that agreement in fiscal 2024 or 2025. Shareholders could face dilution if the company sells shares under the new agreement, but the filing states no amount has been sold and no sales can occur until the registration is effective.
Agreement with Jefferies allows sales of up to $100 million of common stock under the prospectus once the registration statement is effective
Jefferies compensation is up to 3.0% of gross proceeds from shares sold
Shelf registration on Form S-3 covers up to $300 million in debt securities, common stock, preferred stock and other securities
Cantor Fitzgerald sales agreement terminated effective August 28, 2026, with no termination penalties and no shares sold in fiscal 2024 or 2025
Boundless Bio signed Amendment No. 1 to its merger agreement with Serapha Bio on August 28, 2026, changing how Serapha equity awards, certain merger consideration and a share authorization vote are handled. The filing does not state a deal value, and the amendment otherwise leaves the original June 22, 2026 terms unchanged, so shareholders should watch the Form S-4 and proxy statement for the full effect.
Amendment No. 1 dated August 28, 2026; original Merger Agreement signed June 22, 2026 with Serapha Bio, Inc.
Serapha restricted stock units, vested or unvested, convert into Boundless Bio restricted stock units adjusted by the Exchange Ratio
Pre-funded warrants with a $0.00001 exercise price can be issued as merger consideration where share ownership limits would be exceeded
Authorized share increase now requires a majority of shares properly cast, rather than a majority of shares outstanding
On August 26, 2026, RenX Enterprises sold $5,662,716.07 in second senior convertible notes and second warrants in a private placement, with net proceeds of about $5.4 million after fees. The company used the proceeds to repay its February notes at 110% of their outstanding principal, and amended the related agreements to change registration deadlines and liquidated damages terms. The filing shows added debt and potential dilution from conversion and warrant shares, though it does not state a financial result.
Second Notes principal of $5,662,716.07 issued August 26, 2026; net proceeds of about $5.4 million
Up to 11,664,772 shares issuable on conversion at the Floor Price, and 3,520,859 shares under Second Warrants
Proceeds used to repay February Notes at 110% of outstanding principal
Second Registration Statement due 15th calendar day after the Second Closing Date
Coherus Oncology entered an at-the-market sales agreement with Leerink Partners allowing it to sell up to $50.0 million of common stock from time to time, at its discretion. The company is not obligated to sell any shares, and it will pay the agent a commission of up to 3.0% of gross proceeds, so the program could dilute existing holders if used.
Sales Agreement with Leerink Partners LLC dated August 28, 2026, covering up to $50.0 million in common stock
Agent commission of up to 3.0% of gross proceeds from each sale
Shares offered under Form S-3 shelf registration declared effective December 8, 2025
Net proceeds intended for general corporate purposes, including working capital
AiRWA Inc. (Nasdaq: YYAI) received a Nasdaq letter on August 24, 2026, saying it breached a listing rule by not filing its annual report on Form 10-K for the year ended April 30, 2026. The company blamed the delay on the time needed to consolidate a significant acquired business, and says the notice has no immediate effect on trading but that the filing and compliance are not assured.
Nasdaq letter dated August 24, 2026 cites Listing Rule 5250(c)(1) for the late 10-K.
Company must submit a compliance plan by October 23, 2026; Nasdaq may then grant an extension to January 25, 2027.
Company expects to file the 10-K before October 23, 2026, but the filing says there can be no assurance it will regain compliance.
Cumberland Pharmaceuticals said long-term safety and efficacy data from the open-label extension of its Phase 2 FIGHT DMD trial of ifetroban, an oral therapy for Duchenne muscular dystrophy heart disease, is not yet available. The company no longer expects to present the data in August 2026 and intends to present it at a future date. The filing is a schedule update that gives no new trial results.
The data was previously expected to be presented in August 2026, as shown on a slide at the June 26, 2026 Parent Project Muscular Dystrophy conference in Orlando, Florida.
The company says the data is not yet available and no longer expects to present it in August 2026.
No new response, safety or efficacy results were disclosed; no future date was given.
Oragenics said NYSE American notified it on August 26, 2026 that it is below the continued listing standards for stockholders' equity. The company reported stockholders' equity of $3.7 million at June 30, 2026, and the exchange requires $6 million because the company had net losses in its five most recent fiscal years. The notice does not immediately affect the listing, but if the company does not meet the requirements, it could face delisting, which the filing says could reduce the stock's liquidity and market price.
Stockholders' equity was $3.7 million at June 30, 2026; the NYSE American standard cited requires $6 million.
A compliance plan is due to NYSE American by September 25, 2026, and the company must regain compliance by February 25, 2028.
Shares continue to trade as OGEN with a ".BC" (below compliance) designation during the plan period.
The company says it will endeavor to undertake a transaction in the future to achieve compliance, but gives no assurance it will succeed.
Socket Mobile received a Nasdaq notice dated August 24, 2026, saying it no longer meets the $2.5 million minimum stockholders' equity requirement, based on $2,382,624 reported in its June 30, 2026 quarterly report. The company must submit a compliance plan by October 8, 2026, and its stock continues to trade on the Nasdaq Capital Market under SCKT for now.
Stockholders' equity of $2,382,624 versus a $2.5 million Nasdaq minimum
Company also did not meet alternative standards: $35 million market value of listed securities or $500,000 net income from continuing operations
Compliance plan due October 8, 2026; Nasdaq may grant up to 180 calendar days if it accepts the plan
No immediate effect on listing or trading of SCKT common stock
At its August 27, 2026 annual meeting, PEDEVCO stockholders approved the Third Amendment to the 2021 Equity Incentive Plan, raising the plan's share limits from 900,000 to 1,800,000 shares. Stockholders also re-elected six directors, ratified the auditor, and approved executive pay on an advisory basis, with the amendment effective on approval.
The Third Amendment raises the aggregate share pool, incentive stock option limit, and per-recipient award limit from 900,000 to 1,800,000 shares.
Plan amendment approved with 12,007,528.1 votes for, 223,854.4 against, and 14,350 abstentions.
Stockholders elected all six director nominees and chose an annual frequency for future advisory pay votes.
Quorum was about 92.3% of the 13,290,902 shares outstanding as of the June 30, 2026 record date.
Sinclair said its Senior Vice President and Chief Accounting Officer, David Bochenek, will separate from the company effective November 9, 2026, and will receive severance under his 2019 employment agreement. Chief Financial Officer Narinder Sahai will also serve as principal accounting officer from that date, with no added pay for the role.
Separation Date is November 9, 2026; Bochenek stays in his role until then and helps with transition matters.
Severance includes a cash lump sum equal to 24 months of base salary and salary paid through November 30, 2026, plus a bonus of about $66,000 paid over six months.
Bochenek will be available to answer questions on the 2026 Form 10-K until that annual report is filed.
Sahai receives no additional compensation for serving as principal accounting officer.
Norwood Financial Corp's board adopted a stock repurchase program of up to 550,000 shares, about 5% of its issued and outstanding common stock, announced August 28, 2026. The program replaces the repurchase plan the company authorized in 2021, and the filing says repurchases will be made at management's discretion and may be suspended or terminated at any time.
Program covers up to 550,000 shares, approximately 5% of issued and outstanding common stock
Replaces and supersedes the repurchase plan authorized in 2021
Purchases may be made in open market or private transactions, through block trades, or under a Rule 10b5-1 trading plan
The company is not obligated to buy any particular number of shares and may suspend or modify the program at any time
Energy Fuels said its subsidiary completed the acquisition of all ordinary shares of Australian Strategic Materials Limited (ASM) on August 28, 2026, under a scheme implementation deed. The total scheme consideration was about $243.4 million, including $217.2 million in Energy Fuels shares and about $26.2 million in cash, and the company issued 14,808,572 common shares to ASM shareholders, which dilutes existing holders.
Scheme consideration per ASM share: 0.053 Energy Fuels shares (or CHESS Depositary Interests) plus AUS$0.13 in cash
Total consideration about $243.4 million: $217.2 million in shares and about $26.2 million in cash
14,808,572 unregistered Energy Fuels common shares issued on August 28, 2026, under Section 3(a)(10) exemption
ASM option holders received A$0.50 per option under a concurrent scheme
Katapult Holdings' subsidiary CCF OpCo LLC signed a Sixth Amendment to its revolving credit agreement with lenders led by The Huntington National Bank as administrative agent. The amendment extends the scheduled Draw Period Termination Date from August 30, 2026 to September 30, 2026, giving the borrower an extra month to draw on the facility. The filing does not state the facility size or any change in terms beyond the date.
Draw Period Termination Date extended from August 30, 2026 to September 30, 2026
Early termination is possible upon an unwaived Cease Funding Event, and further extensions require lender approval
After a Draw Period Termination Date, a twelve-month amortization period starts, with maturity deferred to its end absent an Event of Default
Amendment is filed as Exhibit 10.1; signed by CFO Russell Falkenstein
Following completion of its business combination with RE/MAX Holdings, Real REMAX Group's compensation committee approved one-time cash bonuses for four executive officers on August 27, 2026. The bonuses range from $100,000 to $400,000 and are disclosed under Item 5.02 because they cover the Chief Executive Officer and Chief Financial Officer. The filing does not describe any change in the executives' roles, and it states no effect on company financial results.
Tamir Poleg (Chief Executive Officer) receives a one-time cash bonus of $400,000.
Ravi Jani (Chief Financial Officer) receives $300,000; Jenna Rozenblat (President) receives $200,000.
Pritesh Damani (Chief Technology Officer) receives $100,000; the four bonuses total $1.0 million.
The compensation committee approved the bonuses on August 27, 2026, in connection with the completed business combination.
On August 24, 2026, Boeing entered a $3.0 billion 364-day revolving credit agreement with Citibank and JPMorgan, replacing a facility that was due to terminate that day. The company also amended its 2024 and 2023 five-year credit agreements to extend their terms and add a minimum liquidity covenant of $5.0 billion. The filing describes committed borrowing capacity and does not state any amounts drawn.
The new $3.0 billion 364-day facility is scheduled to terminate on August 23, 2027, with fees of 0.125% to 0.300% per annum on commitments depending on Boeing's credit rating.
The 2024 Five-Year Credit Agreement ($4.0 billion in commitments) now terminates May 15, 2030; the 2023 Five-Year Credit Agreement ($3.0 billion) now terminates August 24, 2029.
The agreements add or keep covenants including minimum liquidity of at least $5.0 billion and consolidated debt not exceeding 60% of total capital.
Arq, Inc. named Peter Owino Chief Accounting Officer, effective September 1, 2026, after he served as interim CAO under a consulting agreement since June 2026. The filing discloses his $350,000 base salary, target bonuses and 100,000 restricted stock inducement awards, which matter to shareholders as a routine change in the company's accounting leadership with a modest equity grant.
Peter Owino, 52, appointed Chief Accounting Officer effective September 1, 2026; he previously served as interim CAO under a consulting agreement dated June 15, 2026.
Base salary of $350,000; target short-term incentive of 55% and long-term incentive of 75% of base salary.
100,000 restricted stock inducement awards vesting in equal installments over the first three anniversaries of his start date, granted outside the 2026 Omnibus Incentive Plan.
Consulting fees paid to Princeton Business Consulting during the interim period totaled approximately $200,000.
Vyome Holdings appointed Jerry Leonard as Chief Financial Officer on August 27, 2026, with the role taking effect September 1, 2026, under a consulting agreement with ClearbridgeCFO, LLC, which assigns him to the company. The company will pay ClearbridgeCFO a consulting fee of $15,000 per month, and interim CFO Robert Dickey is resigning effective August 31, 2026, which is a change in the company's finance leadership.
Jerry Leonard appointed CFO by board on August 27, 2026, effective September 1, 2026; he will also serve as principal accounting officer.
Consulting fee of $15,000 per calendar month paid to ClearbridgeCFO, LLC; agreement runs one year and renews automatically for 12-month periods.
Robert Dickey resigns as Interim CFO effective August 31, 2026; the filing says the resignation was not due to any disagreement with the company.
Foresite Advisors, LLC consulting agreement dated August 26, 2024 will be deemed terminated as of August 31, 2026.
Vroom's subsidiaries UACC and UACC Auto Financing Trust V signed Amendment No. 11 to their Warehouse Credit Facility with Capital One, N.A. as administrative agent. The amendment pushes the Commitment Termination Date from August 28, 2026 to September 30, 2026, and the filing says all other material terms are unchanged.
Amendment No. 11 was entered into on August 26, 2026.
Commitment Termination Date extended from August 28, 2026 to September 30, 2026.
Capital One, N.A. is administrative agent; all other material terms remain unchanged.
Rainier Acquisition Corporation, a special purpose acquisition company focused on global life sciences, closed its initial public offering on August 28, 2026, selling 7,500,000 units at $10.00 per unit for gross proceeds of $75,000,000 before underwriting discounts and offering expenses. The company placed $75,000,000 in a trust account, and the filing states that trust funds generally stay there until a business combination is completed or specified redemption events occur, with a 24-month deadline from the IPO closing to complete a business combination. Shareholders should note that the filing reports the IPO closing and related agreements, not any target business or acquisition agreement.
IPO closed August 28, 2026: 7,500,000 units at $10.00 each, $75,000,000 gross proceeds; units began trading as RNAQU on Nasdaq Capital Market on August 27, 2026
$75,000,000 placed in a trust account maintained by Continental Stock Transfer & Trust Company; the company has 24 months from IPO closing to complete an initial business combination
Sponsor Ravenna 7 LLC agreed to buy 194,375 private placement units at $10.00 each; underwriters hold a 45-day option for up to 1,125,000 additional units
Wing C. Lam, PharmD and Chidozie Ugwumba were appointed to the board on August 26, 2026; Ugwumba chairs the audit committee
Asana's board appointed Chief Financial Officer Aziz Megji as the company's Principal Accounting Officer on August 26, 2026, in addition to his existing finance role. The filing describes a title addition to an existing executive rather than a departure, and it discloses no new compensation terms.
Board appointed Aziz Megji as Principal Accounting Officer on August 26, 2026.
Megji keeps his current roles as Chief Financial Officer and Principal Financial Officer.
The filing states no arrangements with other persons and no related-party interests for Megji.
GeoVax Labs received a Nasdaq Staff Determination Letter on August 27, 2026, stating Nasdaq will delist its common stock because the bid price stayed below $1.00 and the company is not eligible for the customary 180-day compliance period after its January 2026 reverse split. The company plans to request a hearing before the Nasdaq Hearings Panel, which would stay further action and keep the stock trading during the appeal, but the filing says there is no assurance the panel will grant continued listing.
Nasdaq determined the closing bid price was below $1.00 for 30 consecutive business days from July 16, 2026 through August 26, 2026.
The company effected a 1-for-25 reverse stock split on January 12, 2026, which made it ineligible for the 180-day compliance period.
Absent a timely hearing request, trading is expected to be suspended at the opening of business on September 8, 2026; the hearing request deadline is September 3, 2026.
McCormick director Anne Bramnan, who chairs the Audit Committee, told the Board on August 25, 2026 that she intends to resign. She is leaving to take a new role as Executive Vice President and Chief Financial Officer of Best Buy, and the company says the resignation is not due to any disagreement over its operations, policies, or practices.
Bramnan steps down as Audit Committee chair effective September 1, 2026; Valarie Sheppard takes over as chair that day.
Bramnan remains a Board and Audit Committee member until her resignation takes effect November 30, 2026.
Her reason for leaving is her new role as Executive Vice President and Chief Financial Officer of Best Buy Co., Inc.
The filing states the resignation is not due to any disagreement with the company.
Karman Holdings completed its previously announced acquisition of Walker Precision Engineering for approximately $95 million, or £70 million, in cash, subject to customary adjustments. To help fund the deal, the company increased its term loans by $100 million under a Sixth Amendment to its Credit Agreement, bringing total original term loan principal to $863,961,000. The filing gives no financial results for Walker or for Karman, so its effect on earnings cannot be assessed from this document.
Acquisition of Walker closed August 28, 2026, through a wholly owned subsidiary for about $95 million (£70 million) in cash
Sixth Amendment to the Credit Agreement, dated August 26, 2026, increased term loans by $100,000,000 to a total original principal of $863,961,000
Walker supplies missile seekers, guidance systems and control systems on more than 25 EU tactical missile, air and defense programs
Karman has 17 locations across eight U.S. states; the deal adds a European footprint
Choice Hotels International entered a $500 million unsecured term loan under a credit agreement with Wells Fargo Bank as administrative agent, dated August 28, 2026. The company says proceeds are expected for general corporate purposes, including working capital and debt repayment. The loan adds $500 million of direct debt and comes with covenants limiting dividends and stock repurchases, which may affect shareholder payouts.
$500 million unsecured term loan with scheduled maturity on August 28, 2029, plus an optional one-year extension subject to lender consent
Interest at SOFR (0.00% floor) plus 1.25%, or a base rate plus 0.25%, at the company's election
Financial covenants require a fixed charge coverage ratio of at least 2.5 to 1.0 and a leverage ratio of not more than 4.5 to 1.0, with the fixed charge coverage requirement waived while the company holds an Investment Grade Rating
Agreement restricts dividends and stock repurchases, and the filing lists Wells Fargo Bank, National Association as administrative agent
My Size, Inc. received a Nasdaq letter on August 25, 2026, saying its stockholders' equity of $2,347,000 as of June 30, 2026 fell short of the $2,500,000 minimum for continued listing. The letter has no immediate effect on the listing, but the company must submit a compliance plan by October 9, 2026, and the Staff may grant an extension through February 21, 2027 if the plan is accepted.
Reported stockholders' equity as of June 30, 2026: $2,347,000 versus a $2,500,000 minimum under Nasdaq Listing Rule 5550(b)(1)
Compliance plan due October 9, 2026; the company plans to submit it on time
If accepted, extension possible through February 21, 2027; if not accepted or compliance is not regained, Staff would issue a delisting determination, which a hearing request would stay
Edwards Lifesciences said Donald E. Bobo, Jr., its Corporate Vice President, Strategy and Corporate Development, will retire by mid-year 2027. The company will begin searching for a successor, with the transition expected during 2027. Mr. Bobo is expected to stay on as a consultant through the end of 2027.
Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, will retire by mid-year 2027
A selection process for a successor begins promptly; the transition of duties is expected during 2027
Mr. Bobo is expected to remain as a consultant through the end of 2027
Pinterest's Chief Financial Officer, Julia Brau Donnelly, resigned to pursue another opportunity and will stay until October 30, 2026. The company named Vikram Naidu, its current Vice President, Finance and Business Operations, as interim Principal Financial Officer effective the same day, and has started an external search for a permanent successor.
Donnelly submitted her resignation on August 26, 2026; the company says it is not the result of any disagreement on operations, policies or accounting.
Donnelly remains with Pinterest until October 30, 2026 to support an orderly transition.
Vikram Naidu, age 40, becomes interim Principal Financial Officer effective October 30, 2026, in addition to his current role; he has been Vice President, Finance and Business Operations since March 2024.
Pinterest has commenced an external search to identify a successor to Donnelly.
Lindsay Corporation's board appointed Alicia Pfeifer and Brett Coburn as interim co-Chief Financial Officers, effective September 1, 2026, with Coburn also serving as interim principal financial officer for SEC reporting. The filing describes a change in the company's finance leadership, and a $10,000 monthly stipend for each co-CFO while they hold the added responsibilities.
Alicia Pfeifer, 41, Vice President, Business Finance, and Brett Coburn, 35, Vice President and Chief Accounting Officer, named interim co-CFOs effective September 1, 2026
Coburn also serves as interim principal financial officer for SEC reporting purposes
Each receives an incremental $10,000 per month stipend while holding the co-CFO responsibilities
Pfeifer has been with the company since October 2014; Coburn since April 2019
Peabody Energy said its Executive Vice President and Chief Operating Officer, Darren R. Yeates, will move to a consulting agreement starting February 1, 2027, when his current employment contract expires, running through January 31, 2028. The move is part of the company's ongoing succession planning, and the filing sets out a fixed consulting fee that the company can end at any time.
Consulting agreement signed August 27, 2026; services begin February 1, 2027 and run through January 31, 2028
Minimum monthly consulting fee of $89,773, with up to 40 hours of services per month
Additional fee of $2,244 per hour for work beyond 40 hours in a month
Pool Corporation subsidiaries signed Amendment No. 14 to their receivables securitization facility on August 25, 2026, extending the facility termination date to August 25, 2028. The maximum limit is $400 million from March through September and $300 million in the remaining months, with borrowings priced at one-month Term SOFR plus 0.75% or 0.85%, depending on tranche.
Termination date extended to August 25, 2028, with the agreement effective August 25, 2026
Maximum facility limit of $400 million (March through September): $300 million committed and $100 million uncommitted
Maximum limit of $300 million ($200 million committed and $100 million uncommitted) in the other months of the year
Interest at one-month Term SOFR plus 0.75% (committed) or 0.85% (uncommitted); Wells Fargo Bank, National Association is administrative agent
PTC Therapeutics entered an asset purchase agreement on August 25, 2026 to acquire ST-920, an AAV gene therapy candidate for Fabry disease, from bankrupt Sangamo Therapeutics. The deal carries a $111 million upfront payment plus up to $100 million in contingent milestones tied to FDA approval, and closing requires Bankruptcy Court approval, which is scheduled for a hearing on September 10, 2026.
Upfront payment of $111 million, plus up to $100 million in contingent milestones ($80 million on accelerated approval and $20 million on full approval)
Acquisition is subject to Bankruptcy Court approval (hearing scheduled September 10, 2026) and Hart-Scott-Rodino waiting period expiration
Either party may terminate if closing has not occurred by October 15, 2026, subject to specified exceptions
Representations and warranties do not survive closing and there is no indemnification for breaches
McKesson disclosed that it discovered a cybersecurity incident affecting its information systems on August 25, 2026, and that its investigation is in early stages. The company said it has not determined the incident is material or that it has had, or is reasonably likely to have, a material impact on its financial condition or results of operations.
Incident discovered August 25, 2026; investigation described as in early stages
McKesson has not determined the incident is material as of the filing date
Updates are posted at www.mckesson.com/cybersecurity
Filing dated August 28, 2026, signed by Chief Legal Officer Michele Lau
Nasdaq staff determined to delist Jupiter Neurosciences' common stock from the Nasdaq Capital Market after the company did not regain compliance with the $35,000,000 minimum market value of listed securities by August 25, 2026. The company intends to appeal to the Nasdaq Hearings Panel and expects the hearing request to stay further action, but it cannot assure that the appeal will succeed. Separately, the company regained compliance with the $1.00 minimum bid price requirement, though the delisting threat remains.
Nasdaq notice received August 27, 2026 states the Staff determined to delist the common stock from The Nasdaq Capital Market.
Market value of listed securities was below the $35,000,000 minimum; the compliance deadline was August 25, 2026.
Company intends to request a hearing before the Nasdaq Hearings Panel and expects this to stay further action; success is not assured.
Closing bid price was at least $1.00 for 10 consecutive business days, August 13 through August 26, 2026, and the bid price matter is closed.
Sunshine Biopharma director Dr. Andrew Keller notified the company on August 25, 2026, that he will not seek or accept reelection when his current term ends at the next annual shareholder meeting. The filing discloses no reason for the departure and no financial results, so it is a board-composition change with no stated direct financial effect.
Director Dr. Andrew Keller notified the company on August 25, 2026.
Keller will not seek or accept reelection when his current term expires.
His term ends at the company's next annual shareholder meeting.
The 8-K was signed by CEO Dr. Steve N. Slilaty on August 28, 2026.
Outset Medical said General Counsel John Brottem informed the company on August 27, 2026, that he will leave his role effective September 11, 2026, to pursue other professional opportunities. The filing states the departure is not due to any dispute or disagreement with the company or its management.
John Brottem gave notice on August 27, 2026, and his departure as General Counsel is effective September 11, 2026.
He is leaving to pursue other professional opportunities.
The filing says the departure is not due to any dispute or disagreement with the company or its management.
Trump Media & Technology Group furnished a transcript of interim CEO Kevin McGurn's August 24, 2026 CNBC interview under Regulation FD, with no new financial results in the filing. In the interview, McGurn said Truth API customer count is in the mid-teens and climbing, and described a planned merger of equals with TAE Technologies at a $6 billion valuation, with an S-4 yet to be filed.
McGurn appeared on CNBC's Squawk Box on August 24, 2026; the transcript is Exhibit 99.1.
McGurn said Truth API customers are "in the mid-teens now, and we're climbing" and that the company does not disclose customer names.
An interviewer cited a DealBook report of about ten customers paying $100,000 a month each; McGurn did not confirm that figure.
McGurn said the TAE Technologies transaction would be a "merger of equals" with a $6 billion valuation, and that an S-4 was being prepared.
OFS Capital Corporation issued notice that it will redeem $20,000,000 of its 7.50% Notes due 2028 on September 29, 2026, at 100% of principal plus accrued interest. Of the $69,000,000 of Notes outstanding, $20,000,000 is being redeemed, leaving the remainder outstanding; the filing describes the redemption as routine and does not report a financial result or change in guidance.
Redemption amount: $20,000,000 aggregate principal of the $69,000,000 Notes outstanding
Redemption date: September 29, 2026; price is 100% of principal plus accrued and unpaid interest
Interest on redeemed Notes stops accruing on the Redemption Date; trustee is U.S. Bank Trust Company, National Association
INVO Fertility furnished an investor presentation for use at the H.C. Wainwright 28th Annual Global Investment Conference, September 14 to 16, 2026, and disclosed that it has sold 2,094,395 shares to Alumni Capital LP under a July 24, 2026 purchase agreement for approximately $3,591,000. Shareholders may note the ongoing share sales, which add to the outstanding share count, under a facility with a commitment amount of up to $15 million that could be increased to $50 million by mutual agreement.
Investor presentation to be used at H.C. Wainwright 28th Annual Global Investment Conference, September 14 to 16, 2026, and posted to the Investors section of the company website on August 28, 2026
Shares sold to Alumni Capital LP since SEC effectiveness: 2,094,395 shares for approximately $3,591,000, at an approximate average of $1.71 per share
Purchase agreement dated July 24, 2026 allows the company to sell up to $15 million in shares, with an option to increase to $50 million by mutual written agreement
Aprea Therapeutics announced an update to its intellectual property portfolio covering its precision oncology programs, citing 28 issued and 30 pending patents. The filing reports no financial results, and it does not describe any change in the company's clinical programs or financial position.
Company reports 28 issued and 30 pending patents across its programs.
WEE1 family of applications, if granted, would expire in 2047, excluding any regulatory exclusivities.
ATR inhibitor granted patents expire 2035-2037; pending applications could extend exclusivity into 2045.
Company is considering further development of ATRN-119 in combination therapies after completing dose escalation.
UniFirst said Executive Vice President and Chief Operating Officer Kelly Rooney has resigned to pursue other career opportunities, with her final day expected in mid to late September 2026. The filing says her departure is not the result of any disagreement with the company, and she will receive no severance-related payments because the departure is voluntary.
Kelly Rooney notified UniFirst on August 24, 2026 of her resignation as EVP and Chief Operating Officer
Final day of employment expected mid to late September 2026
No severance-related payments or benefits, as the resignation is voluntary
Steve Chikerotis and Brian Vollant, both Senior Vice Presidents, Operations, will oversee operations on an interim basis, reporting to CEO Steven Sintros
Malibu Boats filed unaudited pro forma financial statements for the fiscal year ended June 30, 2026, as if its March 2, 2026 acquisition of Saxdor Yachts Oy had occurred on July 1, 2025. The combined figures show net sales of $1.05 billion and a net loss attributable to Malibu of $2.2 million, compared with the company's historical net income of $1.7 million. The filing says the figures are for information only and are not a projection of future results.
Pro forma combined net sales of $1,050.9 million versus historical net sales of $914.6 million
Pro forma net loss attributable to Malibu Boats of $2.2 million, or $(0.11) per share, versus historical net income of $1.7 million, or $0.09 per share
Saxdor acquisition closed March 2, 2026, for an aggregate purchase price of approximately $203.9 million
Pluri Inc. agreed on August 26, 2026, to sell 1,200,000 common shares and pre-funded warrants for up to 1,028,940 shares in a registered direct offering, with a concurrent private placement of common warrants for 2,228,940 shares. The offering is expected to close on August 28, 2026, with estimated net proceeds of about $2,984,808 for corporate development, general purposes and working capital. The sale adds shares and warrant exercise rights that could dilute existing shareholders.
Shares priced at $1.50 each; pre-funded warrants priced at $1.49999 with a $0.00001 exercise price
Common warrants exercisable at $1.65 per share, initially six months after issuance, for five years
Placement agent A.G.P./Alliance Global Partners receives a 6.50% cash fee on gross proceeds
Directors and executive officers and the company face 45-day restrictions on new share issuances and sales
Altria's Board increased its size from 10 to 11 directors and elected Steven W. Presley, effective August 27, 2026. Presley was also named to the Board's Compensation and Talent Development, Innovation and Finance Committees, and the Board determined he is independent.
Steven W. Presley elected to the Board effective August 27, 2026; Board expanded from 10 to 11 directors
Presley joins the Compensation and Talent Development, Innovation and Finance Committees
Presley is CEO of Refresco Benelux B.V. and previously held senior roles at Nestlé S.A., including CEO of Zone Americas
Dollar General said its executive vice president and general counsel, Rhonda Taylor, intends to retire, with her move to a senior advisory role effective December 7, 2026. Kelly Collier, currently senior vice president and assistant general counsel for business law, will be promoted to executive vice president and general counsel on that date, giving shareholders a named successor and a planned handover rather than an abrupt change.
Rhonda Taylor advised the company of her retirement intention on August 25, 2026.
Taylor remains general counsel through December 6, 2026, then serves in a senior advisory role through at least April 2, 2027.
Kelly Collier, who joined Dollar General in 2009, becomes executive vice president and general counsel effective December 7, 2026.
Taylor joined the company in 2000 and became general counsel in 2015.
KALA BIO received a Nasdaq Staff Determination Letter on August 27, 2026, stating its common stock closed below $1.00 for 30 consecutive business days and it is out of compliance with the minimum bid price rule. Because the company effected a 1-for-50 reverse stock split on May 11, 2026, it is not eligible for a standard 180-day compliance period, and the company plans to request a Nasdaq Hearings Panel review, which would stay any delisting action while pending.
Nasdaq Staff determined the stock closed below $1.00 from July 16, 2026 through August 26, 2026, 30 consecutive business days.
No 180-day compliance period is available because the company effected a 1-for-50 reverse stock split on May 11, 2026.
KALA BIO intends to timely request a hearing before the Nasdaq Hearings Panel; a timely request stays suspension or delisting pending the Panel's decision.
The company states there is no assurance the Panel will grant continued listing or that it will regain compliance.
Belpointe PREP, LLC approved its quarterly net asset value determination as of June 30, 2026, reporting total NAV of $455,013,467 and NAV of $116.37 per Class A unit across 3,909,902 units outstanding. The filing is a routine valuation disclosure with no prior-period comparison, and the company notes NAV is not a guarantee of realizable value or of unit trading at NAV on the NYSE American.
Total assets of $761,525,631, including $727,299,889 in real property investments
Total liabilities of $306,512,164, including $282,311,738 in debt and other borrowings
NAV of $455,013,467, or $116.37 per Class A unit on 3,909,902 units outstanding
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.